+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comparative uptake retention and action of vincristine vinblastine and vindesine on murine leukemic lymphoblasts sensitive and resistant to vincristine



Comparative uptake retention and action of vincristine vinblastine and vindesine on murine leukemic lymphoblasts sensitive and resistant to vincristine



British Journal of Pharmacology 93(4): 902-908



The uptake and retention of vincristine (VCR), vinblastine (VBL) and vindesine (VDS) were evaluated comparatively with respect to their cytotoxic action on a murine lyphoblastic leukaemia (L5178Y). The same parameters were measured on a derived subline of cells resistant to VCR (L5178Y/r) in order to determine whether the different degree of resistance to each alkaloid correlates with the amount of drug associated with the cells. VCR was the most active on L5178Y cells (IC50 = 5.8.times.10-9M) while the activity of VBL and that of VDS were similar (IC50 4.4.times.10-8M and 3.5.times.10-8M, respectively). Nevertheless, a considerably larger amount of VBL was taken up by the cells compared to VDS, although there were no significant differences in their cytotoxic action. The VCR resistant cell line also expressed resistance to VDS, whose IC50 was increased by a factor of 11.4, but not to VBL. However, the uptake and retention of the three alkaloids were similarly reduced in L5178Y/r cells regardless of the degree of resistance expressed. Although a decreased drug uptake and/or retention by the cells provides an explanation for the resistance to vinca alkaloids, they do not seem to be the only factors accounting for the resistance shown by the cell line which we have isolated. The results seem to indicate that part of the VBL taken up by the cells is not used to induce the cytotoxic effect, but is diverted to some cellular compartment(s) or rate controlling process(es) which are different from the target that mediates its cytotoxic action.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 005002759

Download citation: RISBibTeXText

PMID: 3390658


Related references

Cross-resistance of cultured murine leukemia vincristine-resistant P388 cells to vinblastine, vindesine, and bis (N-ethylidene vindesine) disulfide, disulfate. Journal of the National Cancer Institute 68(6): 1023-1026, 1982

Comparative actions of vindesine vinblastine and vincristine an electron microscopic study in mice using p 388 leukemic cells. Biology of the Cell (Paris) 40(2): 93-98, 1981

Establishment of Vincristine-resistant and vindesine-resistant lines of murine lymphoblasts in vitro and characterisation of their patterns of cross-resistance and drug sensitivities. Cancer ChemoTherapy and Pharmacology 8(2): 163-169, 1982

Cultured leukemia p 388 cells resistant to vincristine p 388 vcr cross resistance to vinblastine nsc 49842 vindesine nsc 245467 and bis n ethylidene vindesine di sulfide di sulfate nsc 277096. Proceedings of the American Association for Cancer Research & American Society of Clinical Oncology 22: 239, 1981

Uptake, initial effects, and chemotherapeutic efficacy of harringtonine in murine leukemic cells sensitive and resistant to vincristine and other chemotherapeutic agents. Cancer Research 43(7): 3074-3079, 1983

Morphological basis for the cytolytic effect of vinblastine and vincristine on cultured human leukemic lymphoblasts. Cancer Research 35(3): 497-501, 1975

Comparative pharmacokinetics of vindesine, vincristine and vinblastine in patients with cancer. Cancer Treatment Reviews 7(Suppl. 1): 17-24, 1980

Comparative effects of vindesine vincristine and vinblastine on tubular formations in electron microscopy. Brade, W , G A Nagel And S Seeber (Ed ) Beitraege Zur Onkologie, Contributions to Oncology, Vol 6 Proceedings Of The International Vinca Alkaloid Symposium: Vindesine; Joint Event Of Arbeitsgemeinschaft Internistische Onkologie Der Deutschen Krebsgesellschaft (Internal Oncology Working Group Of The German Cancer Society) And Eli Lilly Gmbh, Germany, Frankfurt Am Main, West Germany, Nov 1980 Xii+458p S Karger: Basel, Switzerland; New York, N Y , Usa Illus Paper P2-6, 1981

The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer. Medical and Pediatric Oncology 10(2): 115-127, 1982

Comparative effects of vindesine, vinblastine, and vincristine on mitotic arrest and hormonal response of L1210 leukemia cells. Cancer Research 40(8 Pt 1): 2695-2700, 1980

Identification of the bromosulfophthalein-sensitive efflux route for methotrexate as the site of action of vincristine in the vincristine-dependent enhancement of methotrexate uptake in L1210 cells. Cancer Research 48(21): 5995-6001, 1988

Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys. Cancer ChemoTherapy and Pharmacology 12(1): 31-35, 1984

Plasma membrane lipid composition of vinblastine sensitive and resistant human leukemic lymphoblasts. International Journal of Cancer 42(5): 728-733, 1988

Liposome-encapsulated vincristine, vinblastine and vinorelbine: a comparative study of drug loading and retention. Journal of Controlled Release 104(1): 103-111, 2005

Modulation of granulocyte macrophage colonies by vindesine vincristine and vinblastine. Federation Proceedings 40(3 Part 2): 988, 1981